Becker's Healthcare November 18, 2024
Alexandra Murphy

As President-elect Donald Trump prepares to take office, the future of Medicare’s drug price negotiation program, part of the 2022 Inflation Reduction Act, is uncertain, Roll Call reported Nov. 15.

The program, which allows the federal government to negotiate prices for high-cost drugs, is a key policy achievement of the Biden administration, but its future could be affected by changes under the new administration and Congress.

Here are four more things to know:

  1. Upon taking office, the Trump administration will be responsible for implementing the Medicare price negotiation program, which allows the government to negotiate prices on certain drugs starting in 2026. While Mr. Trump has previously supported Medicare price negotiations, his position on the current program...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Insurance, Medicare, Pharma, Pharma / Biotech
Related Articles:
How Medicare Is Causing Patients To Overpay For Prescription Drugs
Podcast: How the Medicare Physician Fee Schedule Will Impact Family Caregivers w/ Jason Resendez
Finalized 2025 Medicare Physician Fee Schedule advances CCM and value-based care with new advanced primary care management codes
Overturning Chevron Doctrine Could Impact Medicare’s Drug Selections For Price Negotiations
Surgeons Billed $2 Billion for Unnecessary Spine Surgeries: Report

Share This Article